Results 51 to 60 of about 3,811,568 (245)

Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators

Asian Journal of Andrology, 2023
Prostate cancer is one of the most common diseases in men worldwide. Surgery, radiation therapy, and hormonal therapy are effective treatments for early-stage prostate cancer. However, the development of castration-resistant prostate cancer has increased
Sayuri Takahashi, Ichiro Takada
doaj   +1 more source

Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.

, 2016
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide.
Blagg, J, Welti, J, Sharp, A, de Bono, JS   +3 more
core   +1 more source

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07) [PDF]

, 2012
The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic target. The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not
Rolf Jaggi, Denise Cotting, Cathomas, R., Brauchli, Peter, Winterhalder, R., Siciliano, D., Pless, M., Schiess, Ralph, Christian Rothermundt, Bubendorf, Lukas, Klingbiel, Dirk, Silke Gillessen, Peter Brauchli, Betticher, Daniel C, Dominik R. Berthold, Cotting, D., Richard Cathomas, Rothermundt, C., Cotting, Denise, von Moos, Roger, Brauchli, P., Berthold, D.R., Miklos Pless, Daniele Siciliano, Ralph Schiess, Winterhalder, Ralph, Gillessen, S., Jaggi, Rolf, Bubendorf, L., Betticher, D.C., Droege, Cornelia, von Moos, R., Pless, Miklos, Lukas Bubendorf, Rothermundt, Christian, Cathomas, Richard, Berthold, Dominik R, Cornelia Droege, Roger von Moos, Daniel C. Betticher, Schiess, R., Klingbiel, D., Ralph Winterhalder, Siciliano, Daniele, Jaggi, R., Droege, C., Gillessen, Silke, Dirk Klingbiel   +47 more
core   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. [PDF]

PLoS ONE, 2012
MicroRNAs (miRs) are small, endogenous, non-coding RNAs that regulate the stability and/or translation of complementary mRNA targets. MiRs have emerged not only as critical modulators of normal physiologic processes, but their deregulation may ...
Reema A Ishteiwy, Toby M Ward, Derek M Dykxhoorn, Kerry L Burnstein   +3 more
doaj   +1 more source

State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer [PDF]

, 2014
Prostate cancer (PrCa) is the most common cancer type in men in developed countries. In the last few years, a dramatic change has occurred in the understanding of castration-resistant PrCa which has led to the development of new drugs that have an impact
Elena Castro, David Olmos, Nuria Romero
core  

Uncovering G Protein‐Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Low‐grade gliomas (LGG) exhibit significant heterogeneity and recurrence risk. G protein‐coupled receptors (GPCR) contribute to glioma malignant progression, but their prognostic value remains unclear. This work attempts to formulate a GPCR‐based outcome‐predicting model for LGG. Methods Based on TCGA LGG data, the enrichment scores
Jun Yang, Dongxu Zhang, Dongyuan Liu, Da Lin, Hao Wang   +4 more
wiley   +1 more source

Systemic treatment for metastatic prostate cancer

Asian Journal of Urology, 2019
The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy ...
Gwenaelle Gravis
doaj   +1 more source

[How should hormone therapy for castration-resistant prostate cancer be continued?] [PDF]

, 2012
After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, and steroidal or non-steroidal antiandrogens, almost all patients with metastatic prostate cancer show PSA progression as a sign of androgen-independent but
Spahn, M, Krebs, M
core   +2 more sources

PARP inhibitors in castration-resistant prostate cancer

Cancer Treatment and Research Communications, 2020
Somatic or germline mutations in genes regulating DNA damage repair have been noted in around 20% of patients with advanced prostate cancer. Poly-ADP-ribose polymerase (PARP) inhibitors have shown encouraging efficacy in prostate cancer patients with DNA repair mutations.
Abhishek Tripathi, Pragathi Balakrishna, Neeraj Agarwal   +2 more
openaire   +3 more sources